Prescriber is the leading UK journal for healthcare professionals focussing on prescribing and medicines management. The journal features articles on all areas of therapeutics and prescribing policy and is fully peer reviewed. The content is relevant and of interest to all prescribers and prescribing policy makers including GPs, pharmacists, nurses and hospital specialists. Access to all content is free to healthcare professionals following registration.Sign up for e-alerts and print copies

Latest News

CCGs failing to declare conflicts of interest

According to a report published by the BMJ (2018;360:j5915), CCGs in England are often failing to declare sources of funding in their public registers. Since...Read more

New GLP-1 agonist recommended for type 2 diabetes

The European Medicines Agency’s (EMA's) Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a marketing authorisation for...Read more

Intranasal esketamine shows promise in treatment-resistant depression

According to a small phase 2 clinical trial published in JAMA Psychiatry (doi: 10.1001/jamapsychiatry.2017.3739), intranasal esketamine has the potential to be...Read more

Guselkumab launched for the treatment of plaque psoriasis

A new biological therapy has been launched in the UK for the management of moderate to severe plaque psoriasis in adults who are candidates for systemic...Read more

NICE recommends cladribine for highly active MS

In a final appraisal determination, NICE has recommended cladribine (Mavenclad) as an option for the treatment of highly active multiple sclerosis (MS) in...Read more

Featured Articles

Update on the use of emergency contraception
In March 2017, the Faculty of Sexual and Reproductive Healthcare issued a new guideline on emergency contraception. This article provides an overview of the current approach to managing emergency contraception to help busy clinicians tailor the most appropriate method to each individual.
Click here to view

The Montgomery judgment and pharmacist consultations
There is little awareness among pharmacists of the existence of the Montgomery judgment or its potential implications for medicines-related consultations. Nina Barnett and Claudia Carr therefore undertook a survey of pharmacists in England to create a baseline for current knowledge about informed consent in the context of medicines-related consultations.
Click here to view

Orphan medicines: the high cost of hope
Orphan drugs can transform the lives of patients with rare diseases, but they often come at an extremely high cost. Sarah Houlton discusses the incentives that are encouraging pharma investment in orphan drug research and the steps that NICE and the NHS are taking to budget for these treatments as they come to market.
Click here to view

Web design and marketing agency Leamington Spa